Low-Dose IV Buprenorphine vs Hydromorphone for Acute Pain in the ED
Low-Dose Buprenorphine Compared With Hydromorphone for Acute Pain in the Emergency Department: A Pragmatic Noninferiority Randomized Clinical Trial
The goal of this study is to compare low-dose IV buprenorphine with IV hydromorphone for adults with undifferentiated acute pain in the Stanford Emergency Department.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
Stanford, California, Forenede Stater, 94305
- Stanford Emergency Department
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Presenting to the Stanford Emergency Department with acute undifferentiated pain
- The treating emergency physician determines that IV opioid analgesia equivalent to 0.5 mg IV hydromorphone is indicated
- Ability to provide informed consent and serial pain assessments
Exclusion Criteria:
- Primary headache
- Contraindication to either study medication
- Pregnancy
- Inability to provide informed consent or serial pain assessments
- Immediate need for procedural sedation or airway management
- Opioid analgesia already received for the current pain episode
- Daily scheduled opioid therapy
- Maintenance treatment with buprenorphine or methadone
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Buprenorphine
The participants receive a single intravenous (IV) 90 mcg dose of Buprenorphine for acute pain in the emergency department (ED). Rescue IV hydromorphone 0.5 mg may be administered after 30 minutes if needed for acute pain. |
Buprenorphine is a partial mu-opioid receptor agonist with a ceiling effect on respiratory depression and a longer duration of action than full agonists.
Andre navne:
|
|
Aktiv komparator: Hydromorphone
The participants receive a single IV dose of 0.5 mg hydromorphone for acute pain in the ED. Rescue IV hydromorphone 0.5 mg may be administered after 30 minutes if needed for acute pain. |
Hydromorphone is a full mu-opioid receptor agonist and a commonly used standard IV opioid analgesic in emergency department practice.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in pain intensity on the 0-10 Numeric Rating Scale (NRS)
Tidsramme: Baseline (pre-randomization), and up to 60 minutes after drug administration
|
Pain intensity is rated on the 0-10 NRS (0 = no pain, 10 = worst pain imaginable). Outcome is the change score (60-minute NRS minus baseline NRS), with a more negative change indicating greater pain relief. |
Baseline (pre-randomization), and up to 60 minutes after drug administration
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Terence Ahern, MD, Stanford University
Publikationer og nyttige links
Generelle publikationer
- Jalili M, Fathi M, Moradi-Lakeh M, Zehtabchi S. Sublingual buprenorphine in acute pain management: a double-blind randomized clinical trial. Ann Emerg Med. 2012 Apr;59(4):276-80. doi: 10.1016/j.annemergmed.2011.10.021. Epub 2011 Nov 23.
- Ahern TL, Ashenburg NG, Park JY, Ognian I, Lee J. Low-Dose Buprenorphine for Acute Pain Management in the Emergency Department: A Prospective Observational Study. Ann Emerg Med. 2025;86(3 Suppl 1). Abstract #141. DOI: 10.1016/j.annemergmed.2025.06.154. Presented at: ACEP Research Forum 2025; September 8, 2025; Salt Lake City, UT.
- Ognian I, Lee JB, Park J, Ahern TL. Safety and Analgesic Outcomes of Low-Dose Buprenorphine for Acute Pain in the Emergency Department: A Retrospective Case Series. J Emerg Med. 2026 Sep;88:48-57. doi: 10.1016/j.jemermed.2026.05.036. Epub 2026 Jun 7.
- Lee J, Ashenburg N, Park J, Ahern T. Intravenous Low-dose Buprenorphine for Acute Pain Management in the Emergency Department: A Case Series. Clin Pract Cases Emerg Med. 2025 Aug;9(3):264-267. doi: 10.5811/cpcem.43494.
- Lee JB, Ognian I, Park J, Coggins N, DeJulio P, Ashenburg N, Ahern T. From Addiction to Acute Pain Relief: A Narrative Review on Buprenorphine's Expanding Role in Emergency Department Pain Management. J Emerg Med. 2025 Dec;79:371-384. doi: 10.1016/j.jemermed.2025.08.038. Epub 2025 Aug 27.
- Mozafari J, Masoumi K, Forouzan A, Motamed H, Saki MA, Dezham M. Sublingual Buprenorphine Efficacy in Renal Colic Pain Relief: A Randomized Placebo-Controlled Clinical Trial. Pain Ther. 2017 Dec;6(2):227-234. doi: 10.1007/s40122-017-0082-5. Epub 2017 Oct 20.
- Payandemehr P, Jalili M, Mostafazadeh Davani B, Dehpour AR. Sublingual buprenorphine for acute renal colic pain management: a double-blind, randomized controlled trial. Int J Emerg Med. 2014 Jan 3;7(1):1. doi: 10.1186/1865-1380-7-1.
- Hickey TR, Costa GPA, Oliveira D, Podosek A, Abelleira A, Avila-Quintero VJ, De Aquino JP. Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials. Reg Anesth Pain Med. 2026 Jan 5;51(1):1-16. doi: 10.1136/rapm-2024-106014.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Smerte
- Neurologiske manifestationer
- Sygdomme i nervesystemet
- Patologiske processer
- Sygdomsegenskaber
- Neuroadfærdsmæssige manifestationer
- Perceptuelle forstyrrelser
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Nødsituationer
- Akut smerte
- Agnosia
- Heterocykliske forbindelser
- Heterocykliske forbindelser, smeltet ring
- Alkaloider
- Polycykliske aromatiske kulbrinter
- Polycykliske forbindelser
- Heterocykliske forbindelser, 4 eller flere ringe
- Morfinans
- Opiatalkaloider
- Heterocykliske forbindelser, bro-ring
- Fenanthrener
- Morfinderivater
- Buprenorphin
- Hydromorfon
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 89536
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .